| Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice LD Mayer, TO Harasym, PG Tardi, NL Harasym, CR Shew, SA Johnstone, ... Molecular cancer therapeutics 5 (7), 1854-1863, 2006 | 391 | 2006 |
| Polylysine and polyornithine gene transfer complexes: a study of complex stability and cellular uptake as a basis for their differential in-vitro transfection efficiency E Ramsay, M Gumbleton Journal of drug targeting 10 (1), 1-9, 2002 | 224 | 2002 |
| Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer CL Messerer, EC Ramsay, D Waterhouse, R Ng, EM Simms, N Harasym, ... Clinical Cancer Research 10 (19), 6638-6649, 2004 | 126 | 2004 |
| Examination of the biophysical interaction between plasmid DNA and the polycations, polylysine and polyornithine, as a basis for their differential gene transfection in-vitro E Ramsay, J Hadgraft, J Birchall, M Gumbleton International journal of pharmaceutics 210 (1-2), 97-107, 2000 | 113 | 2000 |
| Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy AM Thomas, AI Kapanen, JI Hare, E Ramsay, K Edwards, G Karlsson, ... Journal of controlled release 150 (2), 212-219, 2011 | 88 | 2011 |
| Copper–topotecan complexation mediates drug accumulation into liposomes AS Taggar, J Alnajim, M Anantha, A Thomas, M Webb, E Ramsay, ... Journal of controlled release 114 (1), 78-88, 2006 | 87 | 2006 |
| Microfluidics: a transformational tool for nanomedicine development and production S Garg, G Heuck, S Ip, E Ramsay Journal of drug targeting 24 (9), 821-835, 2016 | 74 | 2016 |
| A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug … E Ramsay, J Alnajim, M Anantha, J Zastre, H Yan, M Webb, ... European journal of pharmaceutics and biopharmaceutics 68 (3), 607-617, 2008 | 73 | 2008 |
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo N Jyotsana, A Sharma, A Chaturvedi, R Budida, M Scherr, F Kuchenbauer, ... Annals of hematology 98, 1905-1918, 2019 | 71 | 2019 |
| The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations EC Ramsay, ND Santos, WH Dragowska, JJ Laskin, MB Bally Current drug delivery 2 (4), 341-351, 2005 | 71 | 2005 |
| Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin JHE Baker, J Lam, AH Kyle, J Sy, T Oliver, SJ Co, WH Dragowska, ... Clinical Cancer Research 14 (22), 7260-7271, 2008 | 64 | 2008 |
| Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation E Ramsay, J Alnajim, M Anantha, A Taggar, A Thomas, K Edwards, ... Pharmaceutical research 23, 2799-2808, 2006 | 64 | 2006 |
| Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties EA Ho, E Ramsay, M Ginj, M Anantha, I Bregman, J Sy, J Woo, ... Journal of pharmaceutical sciences 99 (6), 2839-2853, 2010 | 58 | 2010 |
| Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors EC Ramsay, M Anantha, J Zastre, M Meijs, J Zonderhuis, D Strutt, ... Clinical cancer research 14 (4), 1208-1217, 2008 | 58 | 2008 |
| Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications C Walsh, K Ou, NM Belliveau, TJ Leaver, AW Wild, J Huft, PJ Lin, S Chen, ... Drug Delivery System, 109-120, 2014 | 52 | 2014 |
| Current status and future perspectives on MRNA drug manufacturing C Webb, S Ip, NV Bathula, P Popova, SKV Soriano, HH Ly, B Eryilmaz, ... Molecular Pharmaceutics 19 (4), 1047-1058, 2022 | 50 | 2022 |
| Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers DN Waterhouse, KA Gelmon, R Klasa, K Chi, D Huntsman, E Ramsay, ... Current cancer drug targets 6 (6), 455-489, 2006 | 48 | 2006 |
| Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer AG Musende, A Eberding, W Jia, E Ramsay, MB Bally, ET Guns The Prostate 70 (13), 1437-1447, 2010 | 39 | 2010 |
| Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems M Verreault, MS Webb, EC Ramsay, MB Bally Current gene therapy 6 (4), 505-533, 2006 | 34 | 2006 |
| Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia S Mohanty, N Jyotsana, A Sharma, A Kloos, R Gabdoulline, B Othman, ... Cancers 12 (10), 2766, 2020 | 32 | 2020 |
